Cardiac Fibrosis and Risk Prediction in Cancer Treatment-Related Cardiotoxicity
Completed
- Conditions
- Cardiotoxicity
- Registration Number
- NCT02798679
- Lead Sponsor
- University of Minnesota
- Brief Summary
The purpose of this study is to determine whether pre-existing cardiac fibrosis is a predictor of cancer treatment-related cardiotoxicity.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
- Stage I-III breast cancer or lymphoma with a >2 year life expectancy
- A treatment plan that includes anthracyclines and/or trastuzumab
- Age >45 years
- Able to hold breath for 10 seconds
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
Read More
Exclusion Criteria
- Refusal or inability to provide informed consent
- Known heart failure or LVEF <50%
- Heart rate over 100 bpm
- Renal dysfunction with GFR <30 mL/min/1.73m2
- Participants with pacemakers, defibrillators, functioning neurostimulator devices or other implanted electronic devices
- Symptomatic claustrophobia
- Plans to move within 24 months of enrollment
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Cardiotoxicity assessed clinically or by cardiac MRI 24 months
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
University of Minnesota
🇺🇸Minneapolis, Minnesota, United States